Lexicon Pharmaceuticals stock: Cantor keeps USD 8.00 target for Lexicon Pharmaceuticals stock

Published on 10/23/2026 at 04:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cantor Fitzgerald kept USD 8.00 target on October 18, 2026. Lexicon Pharmaceuticals stock posted USD 0.7 million revenue in the second quarter of 2026.

Research and valuation markers

Cantor Fitzgerald maintained its USD 8.00 target on October 18, 2026.
Lexicon reported USD 0.7 million in second-quarter revenue and a USD 31.8 million net loss.
Lexicon Pharmaceuticals is scheduled to report earnings on November 5, 2026.

LXRX, US5288723027, Illustration mit AI erstellt.

Lexicon Pharmaceuticals (ISIN US5288723027) remained under analyst scrutiny after Cantor Fitzgerald maintained a USD 8.00 price target and Buy rating in a report dated October 18, 2026, according to Markets Insider. The target contrasts with Lexicon's clinical-stage operating profile and its latest quarterly loss.

Three milestones reset the story

Lexicon's recent chronology moves from Cantor Fitzgerald's USD 8.00 initiation on September 28, 2026, to second-quarter revenue of USD 0.7 million and a net loss of USD 31.8 million reported on October 6, 2026. The latest event was the October 18, 2026 reaffirmation of the USD 8.00 target and Buy rating by Cantor Fitzgerald, as reported by Markets Insider.

What does the target imply?

The valuation rests on development milestones rather than second-quarter sales. Lexicon completed enrollment in the SONATA-HCM Phase 3 study and expects top-line data in the first quarter of 2027, while management anticipated a Zynquista regulatory resubmission by the end of October 2026, according to Benzinga. The same call showed research and development expenses of USD 17.4 million in the second quarter, up from USD 15.7 million a year earlier, as trial activity increased.

Next dated company event

Lexicon's next scheduled earnings date is November 5, 2026, according to Yahoo Finance. The timing places the next financial update before the first-quarter 2027 SONATA-HCM data window described by management.

Euro quote stays dated

The last available euro quote on Tradegate stood at EUR 1.39 on October 21, 2026. Lexicon Pharmaceuticals is listed on Nasdaq under ticker LXRX, and its market capitalization was USD 663.0 million as of October 22, 2026.